Optopol Revo FC approved for NHS diabetic eye screening programme

BIB Opthalmic Instruments, UK distributor for Optopol, welcomed the official approval, suggesting it would “further aid” early detection and screening of diabetes

A sleek white clinical device with a chin rest positioned before a large camera lens. The logo of Opotpol and Revo FC are in blue and grey on the side

Optopol’s Revo FC Series of optical coherence tomography devices have been approved for the NHS diabetic eye screening programme (NDESP).

BIB Ophthalmic Instruments, the UK distributor for Optopol, shared news of the approval, which came following the diabetic eye screening programme camera assessment day held on 29 November.

Tim Baker, director of BIB Ophthalmic Instruments, commented: “We are delighted with the positive outcome in gaining official approval from the assessment team at NDESP for the Optopol FC OCT series.”

Baker added that having this approval in place would “no doubt” further bolster sales of the device, and “importantly, further aid eye screening departments and patients alike in the early detection and screening of diabetes.”

According to a 29 December update of the guidance Diabetic eye screening: approved cameras and settings, four devices received approval in 2023: the Optopol Revo FC (BIB Ophthalmic Instruments), the Nidek Scan Duo 2 (Birmingham Optical), the Canon CR-10 and Canon Xephilio OCT R1 (Sense Medical).

The assessment days are held every 12 months.